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A B S T R A C T
Cardiovascular diseases, cancer, and diabetes are high mortality diseases, which account for almost two thirds of
all deaths worldwide. Their early detection and continuous evaluation are fundamental for an improved patient
prognosis and reduced socioeconomic impact. Current biosensor technologies are typically based on the analysis
of whole blood samples from patients for the detection of disease-specific biomarkers. However, these tech-
nologies display serious shortcomings, such as reduced sensitivity and dynamic range, limited in vivo applic-
ability, and lack of continuous monitoring. There is the urgent need for new diagnostic and treatment follow-up
tools, which allow for the early detection of the pathology as well as for the continuous monitoring of the
physiological responses to specific therapies. During the last years, a new generation of biosensor technologies
with improved performance has emerged in the biomedical sector. The combination of advanced biomaterial
methods, biochemical tools, and micro/nanotechnology approaches has resulted in the development of in-
novative three-dimensional (3D) biosensor platforms for advanced medical diagnosis. In this review, we report
the most recent advances in the field of 3D biosensors for clinical applications, focusing on the diagnosis and
monitoring of cardiovascular diseases, cancer, and diabetes. We discuss about their clinical performance com-
pared to standard biosensor technologies, their implantable capability, and their integration into microfluidic
devices to develop clinically-relevant models. Overall, we anticipate that 3D biosensors will drive us toward a
new paradigm in medical diagnosis, resulting in real-time in vivo biosensors capable to significantly improve
patient prognosis.
1. Introduction
According to the World Health Organization, ischemic heart dis-
eases, stroke and other cardiovascular diseases (CVDs), were re-
sponsible for 17.7 million deaths worldwide in 2015. Similarly, cancer
and diabetes caused 8.8 and 1.6 million deaths, respectively. All com-
bined, these high mortality diseases killed 28.1 million people, corre-
sponding to approximately 50% of the global deaths (WHO, 2017).
Current diagnostic assays used in the clinics for monitoring CVDs,
cancer and diabetes rely on biomarker quantitation in physiological
fluids, imaging, electrical signals monitoring, and tissue biopsy. These
technologies are typically expensive, time consuming and performed in
different health facilities, which oblige the patients to wait a long time
between analysis and results. Frequently, these techniques also lack the
needed sensitivity and specificity, which makes the results meaningless
and creates the need to repeat the entire process. More importantly, the
current diagnostic procedures lack the ability to continuously evaluate
the physiological condition of a patient and their response to ther-
apeutic treatments, limiting early pathology detection and continuous
treatment follow up (Ahmed et al., 2014). Altogether, there is an urge
for novel diagnostic and analytical technologies, i.e. biosensors, which
are closely connected to the patient physiology and its unique
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metabolic responses. These new generation of devices could be either
implanted into the human body, allowing continuous and real-time
monitoring of disease biomarkers (Muskovich and Bettinger, 2012), or
integrated into an in vitro model (static or dynamic) of a patient disease
to assess the efficiency or toxicity of personalized treatments.
Currently, the major studies in medical biosensors rely on minia-
turized two-dimensional (2D) surfaces with immobilized biorecognition
molecules. However, planar surfaces often present poor analytical
performance, such as narrow dynamic range, instable immobilized
probes and low limit of detection (LoD). These limitations are a direct
consequence of the reduced surface area and surface area-to-volume
ratio, which constrains the amount and efficient capture of a specific
analyte and the signal transduction. Indeed, Barbosa and Reis recently
identified the surface area and surface area-to volume ratio as sig-
nificantly relevant for sensitive detection of protein biomarkers in
point-of-care microfluidic tests (Barbosa and Reis, 2017). Moreover, the
response time of 2D biosensors is typically larger, in particular for lower
LoD, since the analyte relies on diffusion for transportation to the im-
mobilized probe, which sits in a single surface. Furthermore, the effect
of shear stress in a planar surface, due to sample analyte loading, can
remove or inhibit the bond between the analyte and the specific im-
mobilized probe, with significant impact in analytical performance
(Barbosa, 2015). Importantly, 2D biosensors are typically non-flexible,
which aggravates the foreign body response when implanted inside the
human body. Finally, they typically do not allow real-time monitoring
of biomarkers in the three-dimensional (3D) extracellular matrix of
human tissues and organs (Bertok et al., 2014; Edmondson et al., 2014;
Zhu et al., 2015).
The limitations of planar sensing platforms led to the development
of miniaturized 3D biosensors. This new paradigm in biosensing tech-
nologies ally high analytical performance, biocompatibility and 3D
architecture, fundamental for their integration into implantable devices
and in vitro analytical models. In this review, we define 3D biosensors as
those biosensing devices where the biorecognition element is adhered
onto a 3D architecture platform (Fig. 1). These support materials
frequently display enhanced roughness, porosity, or 3D topographic
features. The deposition of vertically-aligned nanotubes, 3D fibers
network, or molecular imprinted polymers (MIPs) also fit within this
category. These engineered 3D structures enhance the electrode area,
and therefore, increase the biorecognition signal. These structures may
vary from the nanometer to the mesoscopic scale, and may be fabri-
cated by a diverse variety of techniques, including standard UV-pho-
tolithography, wet/dry etching, 3D bioprinting, or photopolymeriza-
tion, among other methods (Kassing, 2006; Merceron and Murphy,
2015; Mironi-Harpaz et al., 2012).
The 3D structure of biosensors significantly impacts on the amount
of immobilized biorecognition probes, and as a consequence, on the
analyte capture. It also influences the electrode reaction kinetics, dif-
fusion time, and the shear stress between the analyte and the im-
mobilized specific probe, among other parameters, which translates
into an improved analytical performance (Barbosa, 2015; Barbosa and
Reis, 2017; Faghri et al., 2010). Finally, 3D structures can be easily
combined with biocompatible and flexible materials, making them
especially interesting for implantable applications.
Overall, 3D biosensors show high potential to revolutionize the field
of medical diagnostics. Herein, we review the state-of-the-art of 3D
biosensors, and present a critical evaluation of their performance for
the in vitro and in vivo diagnostics of CVDs, cancer, and diabetes. To this
aim, we discuss about the most common materials used as building
blocks, their fabrication methods, the immobilization procedures, and
the transducers typically employed. We also describe about their in-
tegration into organ-on-chip (OC) platforms and in implantable devices
for advanced clinical applications. Finally, we comment on their cur-
rent market opportunities and how can 3D biosensors be employed to
overcome the limitations of planar sensing technologies to be adopted
by the clinics.
2. Materials and fabrication strategies
The selection of the material and fabrication methodology is fun-
damental in the development of 3D biosensors, since it will affect all the
other components and directly influence their performance. The se-
lected material must synergize both with the biorecognition elements
and the antigen of interest, as well as with the signal transducer
(Colombo et al., 2015; Frascella et al., 2016; Guenther, 2010; L. Li et al.,
2015; Qu et al., 2014; Rong et al., 2015; Slaughter and Sunday, 2014).
A diverse variety of materials displaying different properties can be
used for the development of 3D biosensors, including carbon, glass,
silicon, metals, and polymers, among others. The choice of the adequate
material depends on multiple parameters, such as the type and prop-
erties of the biosensor, the antigen of interest, and the final application
(see Table 1) (Ming et al., 2016; Zhang et al., 2000).
Typically, hydrogels and/or polymers are used for the fabrication of
3D biosensors because they provide a native-like environment for
maintaining the activity of the biorecognition elements, and are com-
patible with 3D micro/nano-fabrication techniques (Derkus et al.,
2015). This also makes 3D biosensors amenable for being implanted
within the human body with minimal immune response, or integrated
into in vitro disease models (Jin and Dijkstra, 2010; Loh and Choong,
2013). Moreover, the use of conductive polymers leads to the fabrica-
tion of conductive hydrogels providing electrical conductivity. This
allows, for instance, the entrapment of oxidoreductases and the electron
transfer, enhancing the performance of glucose biosensors for diabetes
monitoring (Ming et al., 2016; Zhang et al., 2000).
In the last decade, several methods for the fabrication of 3D hy-
drogels have been reported, including freeze-dryer, layer-by-layer, 3D
bioprinting, and photo-polymerization methods (Lu and Li, 2013).
However, hydrogels can also be synthesized through standard chemical
means. These include one-step techniques, like crosslinking of multi-
functional monomers and polymerization, and multiple-step techni-
ques, including the synthesis of polymer molecules and its crosslinking.
Fig. 1. Architectures typically used in 3D biosensors. A) Enhanced surface
roughness; B) Topographical micro/nano-structures; C) Nanotubes; D) Fibers
meshwork; E) Porous materials, and F) Molecular Imprinted Polymers (Key: 1.
Self-assembly; 2. Polymerization; 3. Extraction, and 4. Rebinding).
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The synthesis process plays an important role, since it can tailor the
final hydrogel properties, such as biodegradation, mechanical strength
and chemical and biological response to stimuli (Ahmed, 2015; Akhtar
et al., 2016; Berti et al., 2017; Srisuk et al., 2018).
A large plethora of micro- and nano-sized structures are employed
in 3D biosensors (Fig. 2). These structures enable a closer interaction
with the target molecules and increase the surface/volume ratio, which
drastically improves the electric device performance (Hou et al., 2016;
Malekzad et al., 2017; Zhang et al., 2000). The integration of 3D micro/
nano-structures on biosensors can be obtained by different means, in-
cluding:
(i) In situ fabrication by physical/chemical etching. Typically, etching
techniques such as focused ion beam, oxygen plasma, e-beam,
laser-based lithography, metal-assisted chemical etching, deal-
loying, or standard hydrofluoric acid etching are used, among
many others. Examples of micro/nano-structures manufactured by
these methods include nanoporous metals (gold, alumina, silicon,
silicon oxide, etc.), pillars, tips, cavities, pits, grooves, and others.
As an example, dealloying was recently used to manufacture a 3D
gold nanoporous electrode and applied for the development of a
novel bioelectrode-based biosensor for the direct detection of sul-
fide, an environmental pollutant (Liu et al., 2017). The bioelec-
trode contained recombinant E. coli expressing sulfide:Quinone
oxidoreductase deposited on top of the nanoporous gold electrode
for sulfide detection. The results showed that the remarkable cat-
alytic oxidation properties of the E. coli - 3D gold nanoporous
electrode for sulfide contributed to an improved performance
when compared with standard methodologies, and importantly,
when tested in wastewater.
(ii) Incorporation into a previously existing 3D network forming composite
materials. These materials are very common in biosensors since
each material retains its original properties. The resulting com-
posite displays improved physical, chemical and mechanical
characteristics of those exhibited by each individual material
(Borole et al., 2012; Zhang et al., 2000). Recently, a glucose bio-
sensor based on hollow porous Co3O4 nanododecahedras attached
to a 3D carbon nanotube mesh was developed (S. Wang et al.,
2018). This composite showed a remarkable catalytic activity to-
wards glucose oxidation and an excellent analytical performance,
Table 1
Main advantages and disadvantages of materials for 3D biosensor applications.
Material Advantages Disadvantages
Carbon-based • High conductivity• Low electrical resistivity;• Good mechanical properties;• Easy to functionalize.
× Non- biodegradable;
× Limited data on tolerance by healthy tissues.
Glass/Silicon • Biocompatible;• Good optical and mechanical properties;• Cost-effectiveness.
× Non- biodegradable.
Metals • Good electrical and mechanical properties;• Easy to functionalize.
× Lower biocompatibility (compared to polymers);
× Non- biodegradable.
Polymers • Great biocompatibility;• Able to mimic the natural cell environment;• Can be conductive.
× Poorer mechanical properties (compared to metals).
Fig. 2. Classification and examples of nanostructures according to their dimensions: A) zero dimension (0D); B) one dimension (1D); C) two dimensions (2D), and D)
three dimensions (3D) (Tiwari et al., 2012). Figures reprinted with permission from Elsevier.
R. Rebelo et al. Biosensors and Bioelectronics 130 (2019) 20–39
22
which paves the way for the development of high-performance
electrochemical non-enzymatic glucose biosensors.
(iii) Deposition/growth on a flat electrode surface. Typically, a bottom-up
approach is followed using chemical/physical vapor deposition,
layer-by-layer, inert gas condensation, micelle and inverse micelle
methods, aerosol techniques, sol-gel, electrodeposition, or pre-
cipitation techniques for the deposition/growth of e.g., nano-
particles, anodically-grown TiO2 nanotube arrays, vertically-
aligned–single and multi-walled–carbon nanotubes arrays, 3D-
grown graphene, as well as their nanocomposites (Cassell et al.,
2004; Khalaf et al., 2012; Manawi et al., 2018; Rajput, 2015). For
instance, Singh et al. developed a highly porous 3D nanostructure
for glucose monitoring formed by carbon nanotubes and nano-
diamonds deposited on the electrodes through layer-by-layer
technique. The spatially controlled deposition of these nanos-
tructures was optimized in order to obtain a porous nanostructure
to allow the diffusion of biomolecules of sizes up to 3–10 nm. Next,
an ultrathin polypyrene film was deposited around the 3D struc-
ture for the immobilization of the bioreceptor. The resulting 3D
nanostructure improved drastically the biosensor performance
when compared to the equivalent pure nanotube setup (Singh
et al., 2013).
Typically, hydrogels are used for the fabrication of composite ma-
terials due to their intrinsic mechanochemical properties. In this regard,
we next describe about their use for the development of 3D biosensors,
highlighting their advantages for specific clinical applications.
2.1. Hydrogels
The intrinsic properties of hydrogels make them ideal candidates for
the development of 3D biosensors. Their extremely high water content
facilitates the diffusion of a larger amount of analyte towards the im-
mobilized probes (da Silva et al., 2014; Urban and Weiss, 2009). The
composition of the hydrogel also plays an important role in the bio-
sensor performance. As an example, Colombo et al. developed a sand-
wich-type biosensor for glucose quantification studying the influence of
hydrogel composition on the biosensor response. To this aim, glucose
oxidase (GOX) was mixed with mucin and albumin and then crosslinked
with glutaraldehyde (GA), resulting in the formation of a hydrogel
trapped between two membranes of polycarbonate. The results showed
that these membranes helped to control the diffusion and to reject
eventual interferences. Further, the sensitivity of the GOX sensor was
low when the GA concentration was lower than 3% and when only
mucin was used in matrix preparation. The opposite behavior was ob-
served for higher amounts of GA (Colombo et al., 2015). Similarly, Qu
et al. developed a hydrogel from ferrocene, an artificial electron med-
iator, modified with amino acid phenylalanine for the detection of GOX
via rapid self-assembly mechanism (Fig. 3A). The electron transfer be-
tween the enzyme and the electrode should be taken into account, since
the redox centers of the enzymes are usually deeply embedded in the
thick protein shell. Thus, the introduction of electron mediators, like
ferrocene, facilitate the electron transfer. Hydrogels prepared through
this technique are characterized by its easy preparation process and
functionalization flexibility. Additionally, the resulting hydrogel pre-
sented a simpler molecular structure when compared with other hy-
drogels prepared from peptide and amino acids. The hydrogel bio-
compatibility helped to maintain the GOx bioactivity and the large
number of ferrocene moieties acted as a mediator to GOx. The use of
ferrocene provided a higher sensitivity to the 3D biosensor, in contrast
to glucose biosensors based on oxygen (Qu et al., 2014).
Variations in oxygen concentration are shown to influence GOx-
based biosensor performance either in amperometric enzyme electrodes
or in glucose-sensitive hydrogel (GSH) biosensors. However, the bio-
sensor performance can be independent of the blood oxygen level if the
GSH is enzyme-free. For that, phenylboronic acid (PBA) side chains are
typically incorporated into hydrogels and, in the presence of glucose,
these polymers modify their swelling properties by ionization or by the
formation of glucose-mediated reversible crosslinks. Thus, an increase
on glucose concentration promotes binding leading to a higher hydro-
phobicity and gel swelling. The transference of solvent and solute into
the hydrogel can be controlled by a rigid porous membrane. This way,
combining a “smart” hydrogel and a microfabricated pressure sensor in
a piezoresistive biochemical sensor it is possible to build a biocompa-
tible free-enzyme glucose biosensor (Guenther, 2010).
2.2. Nanocomposites structures
The integration of nanostructures, such as nanoparticles (NPs), into
hydrogels can significantly enhance the performance of biosensors due
to their superior electrochemical behavior and large active surface area
(Kazemi et al., 2016). As an example, Rong et al. (2015) developed a
conducting polypyrrole (PPy)-based hydrogel/AuNPs (gold nano-
particles) 3D electrode for the detection of CEA, a cancer biomarker.
The high porosity of the PPy hydrogel was achieved mixing the PPy
with phytic acid as crosslinker, and ammonium persulfate as initiator.
AuNPs were electrochemically deposited on the PPy-modified elec-
trodes resulting in a 3D nanostructured system. The electrical deposi-
tion was crucial for the dispersion of the AuNPs, which acted as an
immobilization matrix and provided an electrically continuous 3D path
for efficient charge collection. Similarly, Li et al. developed a 3D bio-
sensor based on a platinum nanoparticles (PtNPs) polyaniline hydrogel
electrode for the simultaneous early detection of metabolites associated
to cardiovascular risk, such as uric acid, cholesterol, and triglyceride
(Fig. 3B). The use of PtNPs promoted the effective electrochemical
oxidization in the enzymatic reaction, and the enhancement of the
current collection in overall electrochemical processes (L. Li et al.,
2015).
Other nanocomposite materials, besides hydrogels, with 3D archi-
tecture were also employed for the development of 3D biosensors.
Sabury et al. reported the fabrication of a 3D glucose biosensor through
the immobilization of oxidase on partially reduced graphene–gold na-
nocomposite sheets (PRGO–AuNPs/GOx). Despite the well-known ad-
vantages of graphene, it is reported that the chemically reduced gra-
phene oxide (RGO) may suffer restacking due to van der Waals and
πi–πi interactions, decreasing the surface area and making the proces-
sability difficult. To prevent agglomeration of graphene sheets in dry
state, authors added AuNPs as biocompatible 3D nanostructures
(Fig. 3C). The suitable conditions for graphene reduction were used to
maintain the appropriated conductivity and keep some of the useful
graphene oxide functionalities to ensure communication of im-
mobilized enzyme with the electrode surface. The functional groups
helped to achieve a stable colloid and provide homogeneous mixing of
AuNPs and PRGO without any macromolecular additive. Furthermore,
AuNPs enhanced the electron transfer behavior of the GOx, decreasing
the detection limit and increasing the sensitivity of the biosensor
(Sabury et al., 2015).
Finally, silver-based nano-pinetree arrays and carbon nanotubes
were recently used to develop 3D biosensing devices for the diagnostic
of acute myocardial infarction (Fig. 3D) (El-Said et al., 2016; Gomes-
Filho et al., 2013). Despite the good results obtained in vitro, the well-
known cytotoxicity of silver and carbon nanotubes makes the applic-
ability unrealistic for clinical applications (Arora et al., 2014; Darne
et al., 2014; Knetsch and Koole, 2011; Patlolla et al., 2010; Rai et al.,
2009). Nevertheless, biocompatible coatings may be used to minimize
this problem, although this solution may influence the biomarker im-
mobilization and signal transduction, altering the biosensor perfor-
mance.
3. Probe immobilization
Biosensors for clinical applications must detect a specific analyte in
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complex physiological fluids. For this, biorecognition probes specific to
the analyte of interest need to be immobilized onto a solid support
surface. The amount of captured analyte is intrinsically linked to the
analytical performance of the biosensor, and will depend on the
amount, the affinity, and the activity of the immobilized probes. These
parameters are greatly influenced by the topography of the biosensor
support material (Welch et al., 2017), and the chemical immobilization
technique used (Yu et al., 2015). A 3D biosensor substrate will allow a
larger amount of immobilized biorecognition probes, since it offers
increased surface area when compared with planar surfaces, which are
usually associated with low immobilization efficiency (Gupta and
Chaudhury, 2007; Tanaka et al., 2009; Wang and Feng, 2015). In ad-
dition, 3D material supports can also improve the maintenance the
biological activity of protein probes by minimizing steric hindrance,
providing improved probe orientation and stability for enhanced ana-
lyte capture. This is a direct consequence of not only their high surface
area, but also due to their biocompatibility, permeability and high
water content (Homaei et al., 2013; Kress et al., 2002; Wang and Feng,
2015).
Even though several types of biorecognition probes can be used
(Chambers et al., 2008; Martinkova et al., 2017), here we mainly focus
in the immobilization of enzymes and antibodies, since glucose (dia-
betes) and proteins (CVDs and cancer) are the most used biomarkers for
their diagnosis and monitoring. It may be noted that for diabetes, au-
toantibodies may also be employed as biomarkers due to their high
predictive value. However, their use in the development of biosensors is
still scarce in particular when compared to glucose (Taplin and Barker,
2008). Finally, other protein-based biorecognition probes, such as
peptides (Etayash et al., 2015; H. Li et al., 2015), polymer brushes (J.
Wang et al., 2018), antibody fragments (Saerens et al., 2008), or
membrane proteins (Misawa et al., 2018), have also been employed for
CVDs and cancer.
The state-of-the-art of probe immobilization reveals that the che-
mical immobilization techniques used in 3D environments in the last 10
years are very similar to the ones used on planar biosensors. However,
the overall analytical performance of 3D biosensors is significantly
improved due to the influence of the 3D architecture in the amount,
biological activity, and stability of the immobilized probes.
3.1. Enzyme immobilization
Typically, enzymes are immobilized through their entrapment into
hydrogel pores. This method allows the flow of the analyte of interest
through the 3D hydrogel structure and the immobilization of the en-
zyme, avoiding its denaturation since the enzyme is not necessarily
bound to the polymer (Mohamad et al., 2015). As an example, Qu et al.
developed a glucose sensor using simple entrapment of enzymes within
an hydrogel by mixing GOx during the hydrogel formation process. The
developed sensor displayed a linear range between 0.1 and 20mM,
with a LoD of 50 µM, making this 3D biosensor clinically relevant for
the diagnostics of diabetes mellitus (Qu et al., 2014) (Fig. 4A). The
major drawback of enzyme entrapment is the mass transfer limitation of
the analyte to the enzyme active site. Also, enzyme leakage may occur if
the pores of the support matrix are too large, as well as deactivation
during immobilization, low loading capacity and abrasion of support
material during usage (Górecka and Jastrzębska, 2011). New strategies
have been reported for improving enzyme entrapment in glucose bio-
sensors to improve their performance. For example, GOx enzymes were
first cross-linked and entrapped in a polyethylene glycol hydrogel in a
micropatterned glucose biosensor. However, since the expected bio-
sensor performance was not achieved, further studies were performed
with covalently bond GOx enzymes to modified AuNPs using mercap-
toundecanoic acid and citrate-stabilized (Fig. 4B). The conjugated
AuNPs were then entrapped inside a micropatterned hydrogel (Pedrosa
et al., 2011). Interestingly, this approach allowed a 100-fold increment
on the sensitivity of the sensor. Another approach for improving en-
zyme entrapment was developed by Bornhoeft et al., who reported a 3D
biosensor where GOx was encapsulated inside alginate microparticles
embedded in polyelectrolyte multilayer. The microparticles were em-
bedded in alginate hydrogel with a glucose fluorescent indicator,
creating an alginate-in-alginate response material. The biosensor re-
sponse was given by an immobilized phosphorescent porphyrin dye
inside the alginate microparticles, whose phosphorescence lifetimes
could be correlated with glucose concentration (Bornhoeft et al., 2017).
Fig. 3. Nanocomposites for the fabrication of
3D biosensors. A) SEM image of a hydrogel
prepared from ferrocene modified with amino
acid phenylalanine (Qu et al., 2014). B) SEM
image of PtNPs loaded onto the PAni hydrogel
matrix (L. Li et al., 2015). C) TEM image of
AuNPs distribution into PRGO–AuNP nano-
composite (Sabury et al., 2015). D) SEM image
of Ag nano-pinetree/ITO substrate (El-Said
et al., 2016). Figures reproduced with permis-
sion from ACS publications and Elsevier.
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3.2. Antibody immobilization
Antibodies are globular proteins with specific molecular regions for
antigen binding. Unlike enzymes, antigen-antibody reaction is affinity-
based, therefore stoichiometric in nature. Consequently, the finite sur-
face area in a biosensor, and the lack of biological activity, has an in-
creased negative impact in the analytical performance of biosensors
compared to the enzymatic ones. 3D surface topographies can increase
the amount of immobilized antibody and their biological activity due to
an increment in the total surface area available and antibody molecular
stability, and decrease in denaturation and steric hindrance effects
(Rogers, 2000; Wang and Feng, 2015; Welch et al., 2017).
For instance, Chen et al. reported the development of a 3D biosensor
by adding 11-mercaptoundecanoic and acid/6-mercapto-1-hexanol
(MUA/MCH) monolayer onto a gold surface. This monolayer was fol-
lowed by highly branched dextran amine (DA), which allowed the
formation of a 3D architecture. Finally, acetylated (HA-7) molecules
were added to the branched DA, ensuring the orientation and activity of
the immobilized antibody by affinity binding (Fig. 5A). The char-
acterization of the 3D topography was performed by atomic force mi-
croscopy, which showed an increase in roughness from 3 to 8 nm when
dextran-amine was added to the modified surface (Fig. 5B). To em-
phasize the importance of the 3D topography, antibodies were im-
mobilized directly on the MUA/MCH monolayer, and then, onto DA and
HA-7 peptides. Electrochemical impedance spectroscopy measurements
showed a higher capacity for antibody immobilization on the 3D scaf-
fold, in contrast to MUA/MCH monolayer (Fig. 5C) (Chen et al., 2014).
This enhanced antibody immobilization, together with their
Fig. 4. Enzyme immobilization approaches in 3D biosensors. A) GOx entrapment in a hydrogel made of ferrocene and phenylalanine (Qu et al., 2014). B) Similar
micropatterned manufacture approach, with patterning nanocomposite hydrogels, incorporating AuNPs, previously conjugated with of GOx on Au electrode arrays.
(a) Overall micropatterned process; (b) Covalently binding chemistry of GOx enzymes to AuNPs (Pedrosa et al., 2011). The incorporation of GOx conjugated AuNPs
allowed 100-fold improvement on glucose sensitivity. Figures reproduced with permission from ACS publications and Wiley.
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orientation, impacted on the sensitivity and LoD of osteopontin (OPN)
biomarkers detection. Consequently, the variation in the electron
transfer resistance (ΔRet) upon OPN detection was larger for the 3D
scaffold at every concentration (Fig. 5D). Finally, a broader dynamic
range was obtained for the 3D scaffold.
3.3. Probe-free 3D biosensors
Although enzymes and antibodies provide high specificity and
sensitivity to biosensors, 3D probe-free biosensors have also been re-
ported, in particular for diabetes monitoring. These biosensors have the
advantage of not relying on biomolecules that can lose their activity
over time. This is possible due to material mechanisms, such as the
swelling and stimuli response (Buenger et al., 2012; Deligkaris et al.,
2010). On the other hand, these probe-free biosensors display reduced
sensitivity and specificity compared to their immobilized counterparts.
As an example, Lin et al. reported the development of a glucose-sensi-
tive hydrogel that decreased the volume with the increment of glucose
concentration due to the formation of reversible crosslinks. The dif-
ferences in osmotic swelling pressure were detected by confining the
hydrogel between a porous membrane and the diaphragm of a minia-
ture pressure transducer (Lin et al., 2010). The main issue of enzyme-
free 3D biosensors is that PBA may bind to any molecule containing a
cis-diol. Indeed, the binding affinity of PBA for fructose exceeds that for
glucose. Nevertheless, strategies to overcome this issue have been re-
ported (Tierney et al., 2009). MIPs are gaining an increased attention in
the area of probe-free 3D biosensors since they are able to mimic nat-
ural recognition entities, like antibodies, proteins, and other biological
receptors (see Fig. 1). MIPs are a versatile and promising technique that
promotes selective cavities in a 3D polymeric network (Uzun and
Turner, 2016; Vasapollo et al., 2011). As an example, Widayani et al.
developed a 3D MIP biosensor based on methacrylic acid (MAA) using
glucose as template. The response of the MIP-based electrode depended
on the glucose concentration with a linear behavior from 0.02 to 5mM.
Unfortunately, this concentration range is not appropriate for clinical
settings and further improvement may be required to improve its
analytical performance (Widayani et al., 2017). Overall, even though
probe-free biosensors are simpler compared to their probe-based
counterparts, their performance is still very low, which threatens their
use in the biomedical sector.
4. Detection modes and transducers
Table 2 shows some examples of biosensors for CVDs, cancer, and
diabetes. As it can be observed, there is a diverse variety of detection
modes, materials, and biomarkers that can be employed for disease
detection, which determines the final performance of the biosensor. The
selection of a specific biomarker depends on many factors. Importantly,
among all available biomarkers, some are FDA-approved for clinical
diagnosis, such as CA19.9 for pancreatic cancer, PSA for prostate
cancer, or CEA for colorectal cancer, among others (Mordente et al.,
2015). The interaction between the biomarker and the biorecognition
element is transformed into a readable signal by the transducer. The
transducer can be optical, piezoelectric, electrochemical, or electro-
chemiluminescence, among others. In general, biosensors can be clas-
sified according to their detection mode as electrochemical, piezo-
electrical, optical and magnetic resonance relaxometry (Table 3)
(Dambors et al., 2016; Fan et al., 2008; Frascella et al., 2016;
Grieshaber et al., 2008; Guenther, 2010). Detection modes are similar
on both 2D and 3D biosensors. However, the final analytical perfor-
mance is improved when using 3D platforms, since the signal is am-
plified by the 3D architecture. Further, many transducers can also
display a 3D geometry, increasing the contact area between the bior-
ecognition molecules and the signal detector.
4.1. Electrochemical
Most of the 3D biosensors used in the diagnosis and monitoring of
CVDs, cancer, and diabetes use electrochemical transducers (Chen
et al., 2014; Colombo et al., 2015; Devillers et al., 2017; Elshafey et al.,
2013; Guenther, 2010; Ju et al., 2008; Kazemi et al., 2016; Kunduru
et al., 2010; L. Li et al., 2015; Pedrosa et al., 2011; Rong et al., 2015;
Sabury et al., 2015; Shan and Ma, 2017; Slaughter and Sunday, 2014;
Zanghelini et al., 2017). This is mainly due to their simplicity, high
sensitivity, and low production cost (Hammond et al., 2016). The first
commercial electrochemical biosensor was reported in 1974. It was a
Yellow Springs Instrument Company analyzer (Model 23A YSI) applied
for the direct measurement of glucose, and was based on the ampero-
metric detection of hydrogen peroxide. Since then, electrochemical
biosensors have significantly evolved (Bhalla et al., 2016; Keyes et al.,
1979). As an example, Ju et al. developed a 3D biosensor using an
amperometric glucose transducer with a coiled Pt/Ir working electrode
and an Ag/AgCl reference electrode. The biosensor was exposed to in-
creasing glucose concentrations (5–15mM) and the current responses
were measured. The amperometric response was studied with and
without a porous collagen scaffold covering the electrode, and no sig-
nificant differences were observed in terms of current change. However,
the biosensor integrating the collagen scaffold displayed a longer time
to reach the equilibrium current (Ju et al., 2009, 2008).
An electrochemical technique commonly used in electrochemical
biosensors is electrochemical impedance spectroscopy (EIS). EIS allows
the measurement of the electrical properties of the material (con-
ductivity/resistivity) detecting the electrical changes arising from the
biorecognition at the electrode surface, such as protein immobilization
or antibody-antigen reaction. Interestingly, EIS is a highly sensitive
label-free methodology. This technique measures changes in impedance
upon the application of a small sinusoidal potential (or current) of fixed
frequency. This technique can be affected by several parameters, in-
cluding surface roughness, surface fractal geometry, 3D geometric
distributions, and heterogeneities at the molecule scale (Kafizas et al.,
2017; Zanghelini et al., 2017). As an example, Zanghelini et al. used EIS
to measure atypical glycemic profile of a cancerous mammalian cell.
For that, a TiO2 butterfly-like membrane nanostructures (TiO2-MN) was
used simultaneously as a working electrode and as biorecognition layer
support.
4.2. Optical
Optical biosensors are based on the change in the optical properties
of the material during the interaction of an optical signal with a bior-
ecognition element (Dambors et al., 2016; Fan et al., 2008). 3D mate-
rials amplify changes in the optical properties when compared to planar
surfaces, providing an increment in the analytical performance of bio-
sensors. Optical biosensors can be classified as label or label-free. Most
of the label biosensors use fluorescent-based dyes due to their intrinsic
high sensitivity. Bornhoeft et al. developed a composite hydrogel-based
Fig. 5. Antibody immobilization for the detection of OPN cancer biomarker using a 3D biosensor. A) Schematic of the antibody immobilization using affinity binding
of anti-OPN to acetylated HA-7 peptide on a 3D structure. A gold surface functionalized with MUA/MCH monolayer and branched DA was used as a 3D surface. B)
Atomic force microscopy (AFM) topography images and profiles of the bare gold film (a, b), DA-modified gold surface (c, d), and the HA-7 peptide modified gold
surface (e, f). C) Nyquist plots of the modified electrode prepared stepwise on a) 3D scaffold structure and b) MUA/MCH monolayer. D) Relationship between ΔRet
and antigen concentration for three different conditions ((a): OPN on the 3D structure, (b): OPN on the MUA/MCH monolayer, (c): Bovine serum albumin (BSA) as a
control on the 3D structure) (Chen et al., 2014). Figures adapted and reproduced with permission from: Royal Society of Chemistry.
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system, which was able to optically monitor glucose content. The
composite system was formed by an alginate hydrogel embedded with
alginate microparticles containing Pd-meso-tetra(4-carboxyphenyl)
porphyrin (PdTCPP), GOx and catalase, and coated with PAH (poly
(allylamine hydrochloride)) and poly(sodium-4-s tyrenesulfonate)
(PSS) (Bornhoeft et al., 2017). PdTCPP is a dye responsive to glucose,
through covalently immobilization of oxidoreductase enzymes and it is
oxygen sensitive. Thus, PdTCPP is collisional quenched by molecular
oxygen, being phosphorescence with lifetimes dependent and propor-
tional to the local oxygen concentration. Therefore, the biosensor per-
formance rely on the ability to control the diffusion of oxygen and
glucose through the hydrogel composite. The optical measurements
were performed in a custom-built instrument, with a LED excitement of
530 nm and a silicon photomultiplier detector. Emitted photons were
collected in a ball lens, and the light was collimated and filtered before
arriving to the detector (Bornhoeft et al., 2017).
4.3. Piezoelectric
Piezoelectricity is the ability of some dielectric materials to develop
or change their electrical current when a mechanical strain is applied.
The opposite is also true; if an electrical field is applied to piezoelectric
materials, a mechanical strain is generated. According to these prop-
erties, a piezoelectric material can be used as an electromechanical
transducer. Materials displaying a 3D architecture present a higher
contact surface, which amplifies the piezoelectric signal. Interestingly,
these materials do not require any external power supply, which makes
them especially attractive for biosensor applications. Guenther et al.
developed a 3D glucose biosensor using a piezoresistive hydrogel to
monitor the analyte-induced volume expansion of a polymer layer,
which worked as a chemo-mechanical transducer. A Wheatstone bridge
was included on the hydrogel surface to transduce its deflection into an
electrical output signal. This way, it was possible to continuously
monitor the analyte-dependent swelling of a hydrogel, while the ana-
lyte concentration remained in ambient aqueous solution (Guenther,
2010). Thus, changes in environmental glucose concentration could be
detected through the membrane pores and induce a change in the os-
motic swelling pressure, allowing glucose monitoring (Lin et al., 2010).
4.4. Magnetic resonance relaxometry
This technique reports the measurement of relaxation variables in
MRI. Despite being used as a non-invasive method of biosensing, re-
sonance imaging is extremely expensive. This technique was used for
the detection of β-human chorionic gonadotropin (a multiple cancer
and cervical cancer biomarker) and cardiac biomarkers (cTnI, Myo and
CK-MB–Creatine kinase-muscle/brain) detection, respectively, using a
semi-permeable membrane and magnetic NPs to induce nanoparticle
magnetic relaxation switches (MRSw). The semi-permeable membrane
allowed the respective biomarkers to diffuse into the 3D biosensor, but
not the diffusion of MRSw to tissue environment. MRSw in contact with
biomarkers aggregated, decreasing the transversal relaxation time
(Daniel et al., 2009; Ling et al., 2011). Note that this type of biosensors
can only be used for a finite duration due to NPs saturation. Thus, it is
extremely important to engineer NPs to match the sensitivity and life-
time of the chosen application.
5. Integration of 3D biosensors into microfluidic devices: towards
personalized medicine
The integration of 3D biosensors into miniaturized microfluidic, or
lab-on-a-chip, devices has the potential to revolutionize the field of
point-of-care systems due to the combined advantages of their forming
parts. This combination may provide clinicians with the measurement
of clinical parameters from patients with ultrahigh precision in a fast,
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microfabrication techniques associated with lab-on-chip technology
allows for the miniaturization, automatization, and parallelization of
clinical assays and measurements, reducing the time required for the
analysis and the required volume of sample and reagents. Overall,
microfluidic systems are of high interest for pre-clinical experimenta-
tion and medical applications, which demand for novel devices with
advanced properties capable to detect the presence of a specific com-
pound in physiological fluids with high precision and to predict the
response of drugs in patients. In this regard, organ-on-chip (OC) tech-
nology offers unprecedented possibilities for the development of a new
generation of point-of-care systems with integrated biosensors, which
allow treatment follow-up or better understanding of in vitro persona-
lized disease models. OC are microfluidic devices, which contain
human cells to mimic functional units of a tissue or an organ, re-
capitulating their biomolecular and hydrodynamic properties. OC
emerged as a powerful tool to monitor in real-time the response of
patients to specific therapies to diseases, such as CVDs, cancer, and
diabetes, since they can easily integrate biosensor platforms (Caballero
et al., 2017). These systems offer a precise control of the flow and
microenvironment, which is essential for cell maintenance and growth,
through a continuous supply of nutrients and removal of metabolic
waste, better mimicking what happens in the human body (Halldorsson
et al., 2015).
Even though the use of–2D–biosensors into microfluidic systems is
well-established and a large body of literature is widely available, the
integration of 3D biosensor technologies in OC devices is still far to be
implanted. We examine herein the latest advances on the integration of
3D biosensors into OC systems for the monitoring of clinical-relevant
biomarkers.
5.1. Topographic-based biosensors
As aforementioned, three-dimensional topographies include a di-
verse set of micro- and nano-sized structures, such as pillars, pores,
cavities, grooves, spheres, and fibers (e.g., electrospun fibers, 3D gra-
phene grown fibers, etc.) network, among others (see Fig. 1). These
structures offer a large surface area for bioreceptor loading, which
provides the biosensor platform with a higher sensitivity and selectivity
compared to standard flat sensors. As an example, a microfluidic device
was recently developed to create a microarray-based system to perform
multiple on-chip immunoassays (Han and Koh, 2016). The microfluidic
platform integrated a polysterene-based electrospun nanofiber matrix,
acting as a 3D sensing scaffold, into which a large amount of fluores-
cently-labelled matrix metalloproteinase 9 (MMP-9) peptides were
covalently immobilized. A solution containing MMP-9, an enzyme up-
regulated in several pathologies, such as in cancer (promoting angio-
genesis, cancer cell invasion, and metastasis), was injected into the
microfluidic device leading to the cleavage of a fragment of the labelled
peptide, which diffused toward an observation chamber where the
fluorescence signal was measured (Fig. 6A). A poly(ethylene)glycol
hydrogel frame was used to provide the nanofibers matrix robustness
and control the location of peptide immobilization, restricting the de-
tection only into the microcavities containing the nanofibers. This
system provided low LoD and offered an alternative to standard de-
tection methods using antibodies. Even though the reported sensor se-
lectivity and sensitivity might permit the measurement of MMP-9
within the physiological range, the current response time was still too
long for realistic clinical applications. Future improvement to this work
may include the culture of cancer cells/tissues in the 3D scaffold and
the monitoring of MMP-9 directly from the produced extracellular
matrix.
The secretion of factors out from cells is of high importance for a
vast amount of physiopathological processes. Indeed, their detection is
fundamental to assess the mechanistic determinants of diseases or dis-
orders. However, this secretion critically depends on the observation or
cell culture method. Microfluidic models mimic with higher fidelity the
biological and rheological complexity of the native scenario and
therefore, are an adequate method for the monitoring of cell secretion.
Many sensing approaches have been used for such monitoring. Among
them, microbeads display multiple advantages when integrated in 3D
OC-based biosensors platforms, since they have the capacity to detect
local concentrations of cell-secreted signals. Microbeads can either be
immobilized onto the electrode surface, or be freely mobile within the
microfluidic channel. In this regard, a fluorescent microbeads-based
sensor was recently used combined with a microfluidic system for the
detection of hepatocyte and transforming growth factors (HGF and
TGF-β1), respectively, secreted by a cell layer of primary hepatocytes.
The cells and the sensing chamber were separated by an hydrogel that
allowed secreted factors to diffuse unimpededly, while preventing cells
from crossing over into sensing channels (Son et al., 2017). Indeed,
these growth factors showed to have important roles in tumor devel-
opment and progression. The secretion of growth factors was simulta-
neously monitored by measuring the emitted fluorescence at different
time points using capture microbeads coated with anti-HGF and anti-
TGF-β1. This allowed to obtain HGF and TGF-β1 concentration in the
order of pM (Fig. 6B).
5.2. Entrapment-based biosensors
The detection with high sensitivity and selectivity of molecules truly
depends on the type of 3D transducer. Under certain circumstances, the
detection probe needs to be completely surrounded by a matrix to
provide the system with mechanical support, protecting the detection
probes from degradation, and enhancing overall sensor sensitivity. In
this regard, microfluidic 3D entrapment-based microfluidic biosensors
emerged as an alternative to standard methodologies. As an example,
Jang et al. developed a microfluidic device containing microchannels of
200 µm × 50 µm to entrap GOx and peroxidase (POD) enzymes within
a 3D PEG hydrogel microstructures, and silica-coated silver NPs (Ag@
SiO2) to enhance the fluorescence signal. As a proof of concept, a
10mM glucose solution was injected within the chip into different
channels containing the PEG microstructures with and without Ag@
SiO2 NPs. The fluorescence signal was only observed on the latter, and
importantly, only after 5min after injection (Fig. 6C) (Jang et al.,
2015). Glucose detection was also performed using a droplet-based
microfluidic assay (Piao et al., 2015). In this work, water-in-air droplets
containing a certain amount of glucose, HRP (Horseradish peroxidase),
and Amplex Red probe were injected inside the chip, and the GOx en-
zyme was encapsulated into a hydrogel inside the microchannel. The
droplets passed through the hydrogel where a catalytic reaction with
the immobilized GOx converted glucose and oxygen to gluconolactone
and H2O2, respectively, converting the Amplex Red substrates to the
fluorescent products. The glucose level was quantitatively monitored by
measuring in real-time the fluorescence signal of the droplets induced
by the interaction of the released H2O2 with the HRP (Fig. 6D). The
fluorescence signal was linear with the concentration of glucose, and
concentrations up to 3mM could be detected, with a LoD of 10 µM.
Interestingly, the reusability of the GOx/hydrogel was demonstrated,
paving the way towards re-usable devices.
Even though entrapment-based microfluidic biosensors offer a large
plethora of possibilities, they also present some drawbacks. Large bio-
molecules cannot diffuse within the hydrogels due to the relatively
small mesh size network, limiting their interaction with the entrapped
proteins (Lee et al., 2010). This limits the applicability of this method to
small molecules, such as glucose and DNA, which are important for
diabetes and cancer biomarker monitoring (Han et al., 2017). In this
regard, a 3D hydrogel DNA microfluidic device was developed for the
detection of single-nucleotide variants with high specificity and se-
lectivity (Jung et al., 2015). The chip contained a sequence of photo-
polymerized 3D hydrogels into which the DNA detection probes were
embedded. Electrophoresis was used to rapidly drive the hybridization
of the target DNA towards the different hydrogel chambers containing
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the capture DNA. Single-nucleotide mismatch detection was accom-
plished by performing temperature-gradient electrophoresis, using the
difference in the melting of perfectly matching DNA vs those displaying
a mismatch (Fig. 6E). The device was successfully applied to target DNA
with one base mismatch, displaying an impressive LoD of 1 pM attri-
butable to the high activity of the capture probes in the 3D capture
hydrogels. On the other hand, the performance of the developed device,
capable to only analyze single-stranded DNA targets, as well as the
overall detection time of about 1 h, limits the potential applicability of
the developed device into the clinics. In a follow-up work, the micro-
fluidic device was updated allowing the multiplexed detection of single
nucleotide polymorphism of human clinical samples comprising
double-stranded DNA. In this case, a LoD of 0.024 fM was achieved
using clinical samples (Jung et al., 2016).
6. Implantable 3D biosensors
The idea of having devices inside the human body that can diagnose
a pathology early and monitor health condition can revolutionize
medical care. However, implantable devices capable to detect, quantify,
and transmit the information to the outside still remains a challenge.
First, overcoming the foreign body response is considered one of the
major limitations. Next, the response degree depends on the biosensor
properties, such as its shape, size, roughness, porosity, surface chem-
istry, sterility, implantation duration, and/or degradation time (Onuki
et al., 2008). Then, the maintenance of the activity of the immobilized
probes and the matrix effect can greatly interfere with the analytical
performance of the implanted biosensors. Lastly, the continuous mon-
itoring of analytes, implies long-term stability of the biorecognition
layer, a continuous dissociation of the analyte after the signaling event,
and an effective storage/transmission of data values (Rogers and
Boutelle, 2013; Sasso et al., 2013).
In an attempt to overcome all these challenges, Ju et al. developed a
3D porous collagen scaffold around an amperometric glucose biosensor.
This was crosslinked with nordihydroguaiaretic acid (NDGA) or GA to
improve its biocompatibility and biological stability. To evaluate their
long-term stability, the glucose biosensor was implanted into rats and
assessed weekly over a total of 4 weeks. The sensitivity of the biosensor
dramatically decreased after implantation (when compared with the
pre-implantation values), most probably a consequence of the tissue
damage caused by the foreign body response. However, NDGA-cross-
linked scaffolds presented a higher sensitivity than GA-crosslinked
ones. The formers retained their physical structure with reduced in-
flammation when compared to GA-crosslinked scaffolds (Ju et al.,
2009).
A tight control is a fundamental requirement for the prevention,
diagnostics and management of diseases like CVDs, cancer and diabetes
(Ling et al., 2011). It is, therefore, crucial to use a biosensor with in vivo
long-term stability capable of continuous monitoring while reducing
the transducer degradation and problems associated to implantation
(Sun et al., 2016). In order to overcome these limitations, Ling et al.
developed a magnetic biosensor to continuously monitor changes in
three different biomarkers (Fig. 7A). Superparamagnetic iron oxide NPs
(50 nm) with amine-terminated dextran shells were coupled with
monoclonal antibody against goat IgG. Then, the NPs were
functionalized against specific targets through incubation with goat-
produced polyclonal antibodies against cTnI, myoglobin and CK-MB
and then encapsulated in high density polyethylene devices. The NPs
aggregated around the analyte molecules and altered the transverse
relaxation of adjacent water protons. The developed 3D biosensors were
implanted in murine models and their performance analyzed. Bio-
sensors presented LoDs in the range of 10–100 ng/mL for cTnI, and
100 ng/mL to 1 μg/mL to myoglobin and Ck-MB, which although it is
not enough for clinical application, is significant considering mea-
surements for in vivo performance. Nevertheless, it is important to note
that biosensors saturated at ≈1.5 μg h/mL, which is a huge constraint
for the biosensor lifetime and cardiac monitoring duration (Ling et al.,
2011). The same strategy was applied by Daniel et al. for the detection
of hCG-β cancer biomarker. Biosensors of high density polyethylene
(HDPE) were produced and functionalized with MRSw coated with anti-
hCG-β95 and anti-hCG-β97. Next, they were implanted in mice showing
a detection range between 0.5 and 5 μg/mL hCG-β and a LoD of 0.5 μg/
mL. The evaluation of biosensor performance was limited by the lack of
correspondence between the biomarker concentration in naturally oc-
curring tumor and the xenograft tumor model used. In the latter, the
biomarker concentration was significantly higher, which is not re-
presentative of the real physiological environment. Similarly, the long-
term stability of the biosensor was not studied (Daniel et al., 2009).
With the aim of using less invasive techniques, Sun et al. developed
a strategy for the real time and dynamic monitoring of small molecules
in vivo by using a fluorescent semiconductor polymer dots (Pdot)
oxygen transducer. GOx-functionalized Pdots were used for the con-
tinuous monitoring of glucose levels. Pdots transducer consisted in a
semiconductor polymer (PDHF-Poly [9, 9-di-(2′-ethylhexyl) fluorenyl-
2,7-diyl]) doped with platinum octaethylporphyrin (PtOEP), an oxygen
sensitive phosphorescent dye. The changes in oxygen concentration
promoted by glucose levels were transduced into an optical signal (Sun
et al., 2016). Next, Pdot-GOx NPs were implanted in a mice model for a
period of 30 days through a subcutaneous injection (Fig. 7B). Due to
their extraordinary brightness, the concentration of glucose in the mi-
crogram range was detectable transdermally. After the implantation
time the biosensor luminescence still correlated with glucose levels and
no damage was observed in the mice organs. However, a decrease in
sensitivity was observed most likely due to a decrease in enzyme’s
catalytic activity in Pdots surface. Despite the promising results the
long-term monitoring was studied only for 30 days, which is still a short
period of time (Sun et al., 2016).
Actual examples of 3D biosensors employed for clinical applications
are scarce. Many reasons may be behind this low adoption rates, such as
their higher complexity compared to standard–planar–technologies, the
lack of standardization or certification (e.g., FDA-approved), and in
particular for implantable devices. As aforementioned, it is not yet not
well understood how foreign body response (e.g., inflammation) on
implanted devices may hamper the clinical biomarkers detection. In
addition, it needs to be investigated whether the formation of a fibrous
capsule surrounding the biosensor may cause a significant loss of its
performance over time. Next, the swelling of 3D biomaterials (e.g. hy-
drogels), their permeability to different molecules, their interaction
with different media, and the optimal immobilization of biomolecules
may need to be optimized to ensure an optimal biosensor performance.
Fig. 6. Integration of 3D biosensors into microfluidic devices. A) (Top) Scheme showing a nanofiber 3D matrix integrated within a microfluidic device for the
detection of MMP-9. (Bottom) Optical fluorescence images showing the microfluidic array detection system before and after the reaction between the MMP-9 and the
fluorescent-labelled peptides (Han and Koh, 2016). (B) (Top) Scheme showing a 3-channel microbead-based microfluidic sensor for the detection of cell-secreted
growth factors. (Bottom left) Hepatocyte culture and sensing channel inside the microfluidic device. (Bottom right) Fluorescent images of the release and detection of
HGF (in red) and TGF-β1 (in green) (Son et al., 2017). (C) (Top) Scanning electron and optical fluorescence microscopy images of the hydrogel microarrays injected
into a microfluidic system entrapping Ag@SiO2 and enzymes, and used for the detection of glucose (in red). (Mid and bottom). Hydrogel microarray with and without
Ag@SiO2 after glucose exposure (Jang et al., 2015). (D) (Top) Biochemical reaction for glucose detection. (Bottom) Fluorescent images showing the different droplet
intensities after their exposure to different glucose concentrations (Piao et al., 2015). (E) Microfluidic hydrogel-based array used for the detection of single nucleotide
polymorphism. (Jung et al., 2015). Figures adapted and reproduced with permission from the ACS publications, Nature, Royal Society of Chemistry and Elsevier. (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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To address all these challenges several clinical trials are currently under
investigation aiming to introduce biosensors in the clinics in the near
future (see also Sections 7 and 8). The successful widespread applica-
tion of 3D biosensors in current clinical applications will definitely
require contributions from different fields, such as microelectronics and
nanotechnology. This will help to standardize all the manufacturing
processes and to provide the needed stability and reliability requested
by the clinicians and pharmaceutical companies (Carpenter et al., 2018;
Hasan et al., 2014; Zhu et al., 2015). Finally, the use of new approaches
in signal transduction, such as wireless, polymer-dots or magnetic
particles may boost their adoption by the healthcare market.
7. Commercialization and regulatory issues: from lab to the
market
The development of 3D biosensors, and their integration into im-
plantable medical devices and OC-based disease models, have the po-
tential to offer great market opportunities to pharmaceutical and bio-
technological companies. Similarly, the reduction of the costs
associated to drug discovery and screening, and the increase in the
reliability of drug testing, makes 3D biosensors also appealing for
clinical applications. The national healthcare systems may also benefit
from their development by reducing the high cost associated to public
healthcare. However, for this to become a reality, many constrains and
challenges need to be addressed. These challenges are similar to those
encountered by planar sensing platforms, which are mainly technical
and have been broadly discussed above. However, the integration of 3D
biosensors into implantable medical devices is additionally associated
with a major constrain: the complex regulatory issues for clinical pro-
ducts. For clinical application, medical devices must go through a long
and careful regulation process before commercialization to ensure the
device safety under the strict supervision of the regulatory agencies
(FDA–Food and Drug Administration in US, and CE–European
Conformity in EU) (Fiedler and Ferguson, 2017; Mazzocchi, 2016;
Meng, 2014; Pina et al., 2018). Usually, it begins by the development of
the product in the laboratory under GMP (good manufacturing
practices) conditions, followed by animal testing in a highly controlled
environment, and finally, clinical trials. In this regard, a thorough
survey using several international databases (Clinicaltrials.gov, the In-
ternational Clinical Trials Registry Platform–WHO, the European Or-
ganization for Research and Treatment of Cancer–EORTC, the EU
Clinical Trials Register, the European Cancer Patient Coalition–ECPC,
and the Australian New Zealand Clinical Trials Registry–ANZCTR) re-
ported several clinical trials around the world of biosensors for cancer,
CVDs, and diabetes applications. However, in most of the cases, very
few information about the biosensor characteristics was reported (see
Table 4).
The absence of product development guidelines also contributes to
the low level of development of medical devices integrating 3D bio-
sensors. Indeed, 3D biosensors research still need to work towards
improving the long-term performance in complex biological environ-
ments. However, there is a global effort to increase the investment le-
vels in translational research, in particular for healthcare applications.
This effort is beginning to be recognized by the number of patents
(∼50) regarding 3D biosensors in the last few years (WIPO database)
with potential industrial and clinical applications (Table 5). Similarly,
several high-tech, biotechnological and pharmaceutical companies are
investing a large amount of resources in developing diagnostic and
biosensing devices, such as Medtronic™, Phillips™, Abbott™, Dexcom™,
Endotronix™, CellNovo™, iRhythm Technologies™, LivaNova PLC,
Roche™, or Profusa™, among many others. The latter is developing a
porous hydrogel linked to a light fluorescent-emitting molecule that
produces a signal in the presence of glucose or any other biomarker of
interest, which is monitored by a separated optical reader. Interest-
ingly, this device can be adhered to the skin or held by hand (“Profusa,
Inc.,” n.d.). Other companies are also commercializing their own pro-
ducts (e.g., implantable cardiac defibrillators (Medtronic™), Cardio-
mems™ heart failure monitoring system (FDA-approved; Abbott), the
Cordella™ heart failure sensor (Endotronix™), or the Enlite™ glucose
sensor (Medtronic™)), or evaluating their performance in the clinical
trials (see Table 4). In this regard, most of the reported clinical trials are
related to heart failure monitoring and stimulation and for the
Fig. 7. Implantable 3D biosensors. A) Magnetic resonance
relaxometry 3D implantable biosensor. (i) The sensor con-
sists on a reservoir containing MRSw particles enclosed by a
size-exclusion membrane. (ii) Feasibility of MRI-based in situ
measurements after 24 h implantation with acute myo-
cardial infarction (MI) and without (control) (Ling et al.,
2011). B) Pdot-GOx biosensor function mode. (i) Schematic
of insertion of a Pdot-GOx biosensor and Pdot transducer
function mode. (ii) Fluorescence images of different glucose
concentrations of the implanted biosensor by luminescence
intensity (Sun et al., 2016). Figures adapted and reproduced
with permission of Nature and ACS publications.
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continuous monitoring of the glucose levels. In contrast, few cancer-
related devices, in particular, with implantable characteristics have
been described.
8. Unmet needs and future perspectives
The current level of development of 3D biosensors makes their
translation to the clinics in the near future unrealistic despite some
successful exceptions (see Tables 4 and 5). In particular, it is not yet
clear whether 3D biosensor can actually solve the limitations of current
biosensing technologies in the clinical settings. One of the main reasons
is that typically, most of the tests for in vitro biomarker detection per-
formed in the laboratory use simplified matrices and not physiological
samples, which reduce the sensitivity and selectivity of biosensors. In
fact, even though 3D biosensors display suitable analytical performance
in the laboratory settings, they are still far from being applied in the
clinics in a regular basis, in particular, as implantable devices. Several
serious limitations 3D biosensors must address before being adopted,
include their multiplex capability, reproducibility, assay duration, sta-
bility, or the exploration of novel biomarkers, among others. Multiplex
capability can easily be achieved using microfluidic in vitro system,
where multiple microchannels and 3D chambers could be integrated
together with the sensing entities. This allows the simultaneous detec-
tion of several analytes (Misun et al., 2016). Similarly, static 3D
biosensor may also display multiplex capabilities. To this aim, an array
of 3D porous structures or topographic micro/nano-structures may be
employed, with several regions containing the different biorecognition
elements. Indeed, these approaches were recently employed for the
detection of cancer and cardiovascular biomarkers, resulting in a per-
formance similar to the one obtained with standard and time-con-
suming laboratory techniques (Nikitin et al., 2018), and importantly,
reducing the time of the assay. However, their in vivo multiplex per-
formance still remains a challenge. The use of transdermal 3D biosensor
integrating multiple 3D micro/nano-needles (each of them detecting
the different analyte) may provide a plausible solution to the multiplex
capabilities of the implantable devices.
3D biosensors may also improve the reproducibility of the assays, a
pitfall in the biosensors field, by increasing the stability of the bior-
ecognition layer. In planar biosensor platform, this layer is more ex-
posed to the harsh environment in contrast to 3D biosensors, where the
layer is more protected, in particular in porous 3D structures or hy-
drogels. In addition, 2D biosensors are more prompt to saturation and
to the adhesion of non-specific proteins (corona effect). Due to the
enhance surface-to-volume ratio of 3D biosensors, which also increases
the number of capture probes, they are expected to display less varia-
bility and fluctuations in the measurements, thus contributing to an
enhanced reproducibility of the data. In this regard, real-time con-
tinuous measurement is also a major challenge of current biosensing
techniques; the response cycles are still too long and the signal stability
is still not robust enough. As aforementioned, the superior architecture
of 3D biosensors may increase sensor sensitivity and selectivity, thus
allowing real-time measurements.
Next, 3D biosensors may also allow exploring, revisiting, and using
new–unexpected–biomarkers considered as non-adequate for planar
biosensing technologies. The enhanced sensitivity of 3D biosensors may
allow re-using biorecognition elements discarded, thus offering a larger
catalogue of capture probes. In particular, this may be fundamental for
diabetes, since most of the studies are based on the periodic detection of
glucose levels in blood. The use of alternative biomarkers compatible
with other body fluids (e.g., saliva) may open up the new avenues,
which may avoid blood extraction using (semi)-invasive methods
(Ladgotra et al., 2016; Srinivasan et al., 2015).
In general, cancer and diabetes are more chronic diseases than
CVDs. The formers require high sensitivity and specificity for their early
detection and prognosis, whereas the latter require a fast assay time. In
this regard, the needs for detection of these diseases are not exactly the
Table 4
Most relevant clinical trials on biosensors for CVDs, cancers, and diabetes.
Trial ID (Year) Application Status Title Comment
NCT02545166 CVD Active Validation of a Purine Biosensor in Detecting Acute Cerebral
Ischaemia: Carotid Endarterectomy Model in SMARTChip (CEMS)
In vitro; detection of blood purine levels.
(2016-2019)
NCT02308605 CVD Completed SMARTCap Stroke Study: A Field Deployable Blood Test for Stroke
(SMARTCAP)
In vitro; detection of blood purine levels (early
biomarker of brain ischaemia).(2014-2016)
NCT03247829 CVD Active Investigation to Optimize Hemodynamic Management of Left
Ventricular Assist Devices Using the CardioMEMS™
Implanted; direct pulmonary artery pressure
monitoring; FDA-approved.(2017-2019)
NCT03375710 CVD Active SIRONA Trial Heart Failure NYHA Class III Implanted; pulmonary artery pressure sensor;
first-in-human implantation.(2017-2020)
NCT02957370 Cancer Active Molecular Biosensors for Detection of Bladder Cancer In vitro; detection of urinary anomalies.
(2015-2020)
NCT02195076 Cancer Completed Non Invasive Detection of Lung and Breast Cancer by Odor Signature Ex vivo; detection of volatile compounds.
(2014-2017)
NCT03173729 Cancer Active Point of Care, Real-time Urine Metabolomics Test to Diagnose
Colorectal Cancers and Polyps in Low and Middle Income Countries
In vitro; detection of urine biomarkers.
(2017-2022)
NCT03445065 Diabetes Active Benefits of a Long Term Implantable Continuous Glucose Monitoring
System for Adults With Diabetes - France Randomized Clinical Trial
Implanted (subcutaneous); continuous
monitoring of glucose levels.(2018-2019)
NCT01991470 Diabetes Completed A Performance Evaluation of the Enlite™ and Enlite 3 Glucose Sensor
to Support Use in Children(2015-2016)
NCT01065948 Diabetes Completed A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity
Sensor (FAS) Performance and Safety Over Several Hours(2009-2012)
ACTRN12617000919314 Diabetes To be opened Investigation of a long-term continuous glucose monitor in type 1
diabetes(2017)
Table 5
Most significant patents in the 3D biosensors field.
Patent Number (Year) Title
US20180045681 System and method of measuring cell viability and
growth.(15.02.2018)
KR1020160124013 Biosensor for monitoring 3D cell culture in real time.
(26.10.2016)
US20140011697 3D RF MEMS biosensor for multiplexed label free
detection.(09.01.2014)
US20130206595 Biosensor with three-dimensional structure and
manufacturing method thereof.(15.08.2013)
US20100066346 Fabrication of microstructures integrated with
nanopillars along with their applications as electrodes
in sensors.
(18.03.2010)
EP2088430 Biosensor having 3D metallic nanowire electrodes
forming nanochannel, manufacturing method thereof,
and bio disk system having same.
(12.08.2009)
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same, thus 3D biosensor must display a large plethora of possibilities in
terms of configuration, materials, and analytical performance. This al-
lows their use in a wide variety of physiopathological processes. For
cancer applications, the enhanced sensitivity given by the 3D archi-
tecture of the electrode/biorecognition layer provides the needed sen-
sitivity and specificity. In addition, the multiplex capability mentioned
above allows a multi-parametric detection of analytes associated with
the disease at early stages. This also holds true for diabetes, where the
enhanced sensitivity may prevent the measurement of glucose levels in
blood by measuring the presence of biomarkers, for example, in saliva.
Finally, for CVDs, the use of implantable devices allows for a con-
tinuous monitoring of heart activity capable to detect and prevent heart
failure.
Finally, it is yet not well understood the reaction kinetics occurring
on the electrode in 3D biosensors, as well as other physicochemical
phenomena (electron transfer kinetics, double layer capacitance,
Warburg–diffusion–impedance, and others), which may affect the
signal recorded on the electrode. This is in particular fundamental in
highly porous structures in order to understand the origin of the de-
tected signal. Some works have reported on the electrochemical beha-
vior of biosensors depending on the structure of 3D pore electrode,
showing the critical relation between diffusion and biosensor perfor-
mance (Ye et al., 2015). Similarly, it was shown that the interplay be-
tween the pore size, and the coating and electrode thickness plays a
fundamental role for improved sensor response. The impact of enzyme
distribution in 3D porous electrodes has been recently addressed
(Mazurenko et al., 2017). Typically, enzyme distribution has been
considered homogeneous. In this work, it was shown that only 10–15%
of the total quantity of adsorbed enzymes contributed to the catalysis.
Further, simulation studies have been performed for a rational design of
3D porous electrodes with enhanced selectivity and sensitivity
(Halhouli et al., 2016). In this case, not only the size but also the
number of pores influence the diffusion within the electrode due to an
enhanced diffusion resistance.
9. Conclusions
Cardiovascular diseases, cancer and diabetes are worldwide high
rate mortality diseases. Their early prognosis urge new medical tech-
nologies able to continuously screen and monitor specific biomarkers
and to overcome the limitations associated to standard 2D-based bio-
sensing technologies. 3D biosensors offer a large plethora of advantages
when compared to flat biosensor devices, in particular in terms of the
improved sensitivity and stability. The 3D architecture of the electrodes
maximizes the amount of immobilized probes and the electron transfer,
which contribute for the improved performance. They also offer en-
hanced implantable characteristics, fundamental for the continuous and
real time monitoring of the disease. They may also be integrated into
physiologically-relevant OC platforms to evaluate and predict the effi-
ciency of personalized treatments with high sensitivity and reliability
prior moving to the patient. These innovative technologies demand
high performance, flexible, and biocompatible 3D biosensor platforms.
In this regard, a new generation of 3D biosensors have emerged.
However, moving to the third dimension in biosensors is associated
with the appearance of critical physicochemical phenomena, which
need to be fully considered if intended to improve biosensors perfor-
mance. In this way, 3D biosensors will be capable to revolutionize
disease detection, monitoring and treatment follow-up of high mortality
diseases. Nevertheless, further integration of biosensing technology
with tissue engineering approaches needs to be accomplished, trans-
lating the results obtained in the lab into commercially viable products.
This is a long and judicious process, in which strict and specific re-
quirements need to be fulfilled, under the severe guidance of interna-
tional regulatory entities, before its implementation into the medical
market.
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